Literature DB >> 19632331

Absence of a differentiation defect in muscle satellite cells from DM2 patients.

Richard Pelletier1, Frederic Hamel, Daniel Beaulieu, Lysanne Patry, Caroline Haineault, Mark Tarnopolsky, Benedikt Schoser, Jack Puymirat.   

Abstract

Myotonic dystrophy type 1 (DM1) and type II (DM2) are dominantly inherited multisystemic disorders. DM1 is triggered by the pathological expansion of a (CTG)(n) triplet repeat in the DMPK gene, whereas a (CCTG)(n) tetranucleotide repeat expansion in the ZNF9 gene causes DM2. Both forms of the disease share several features, even though the causative mutations and the loci involved differ. Important distinctions exist, such as the lack of a congenital form of DM2. The reason for these disparities is unknown. In this study, we characterized skeletal muscle satellite cells from adult DM2 patients to provide an in vitro model for the disease. We used muscle cells from DM1 biopsies as a comparison tool. Our main finding is that DM2 satellite cells differentiate normally in vitro. Myotube formation was similar to unaffected controls. In contrast, fetal DM1 cells were deficient in that ability. Consistent with this observation, the myogenic program in DM2 was intact but is compromised in fetal DM1 cells. Although expression of the ZNF9 gene was enhanced in DM2 during differentiation, the levels of the ZNF9 protein were substantially reduced. This suggests that the presence of a large CCTG tract impairs the translation of the ZNF9 mRNA. Additionally, DM2 muscle biopsies displayed the altered splicing of the insulin receptor mRNA, correlating with insulin resistance in the patients. Finally, CUGBP1 steady-state protein levels were unchanged in DM2 cultured muscle cells and in DM2 muscle biopsies relative to controls, whereas they are increased in DM1 muscle cells. Our findings suggest that the myogenic program throughout muscle development and tissue regeneration is intact in DM2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632331     DOI: 10.1016/j.nbd.2009.07.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  34 in total

1.  Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel.

Authors:  Zhen Zhi Tang; Viktor Yarotskyy; Lan Wei; Krzysztof Sobczak; Masayuki Nakamori; Katy Eichinger; Richard T Moxley; Robert T Dirksen; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2011-12-02       Impact factor: 6.150

Review 2.  Are human and mouse satellite cells really the same?

Authors:  Luisa Boldrin; Francesco Muntoni; Jennifer E Morgan
Journal:  J Histochem Cytochem       Date:  2010-07-19       Impact factor: 2.479

3.  Reduction of Cellular Nucleic Acid Binding Protein Encoded by a Myotonic Dystrophy Type 2 Gene Causes Muscle Atrophy.

Authors:  Christina Wei; Lauren Stock; Christiane Schneider-Gold; Claudia Sommer; Nikolai A Timchenko; Lubov Timchenko
Journal:  Mol Cell Biol       Date:  2018-06-28       Impact factor: 4.272

4.  Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2.

Authors:  Olayinka Raheem; Shodimu-Emmanuel Olufemi; Linda L Bachinski; Anna Vihola; Mario Sirito; Jeanette Holmlund-Hampf; Hannu Haapasalo; Yi-Ping Li; Bjarne Udd; Ralf Krahe
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

5.  RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2.

Authors:  Karlie Jones; Bingwen Jin; Polina Iakova; Claudia Huichalaf; Partha Sarkar; Christiane Schneider-Gold; Benedikt Schoser; Giovanni Meola; Ann-Bin Shyu; Nikolai Timchenko; Lubov Timchenko
Journal:  Am J Pathol       Date:  2011-09-01       Impact factor: 4.307

Review 6.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

Review 7.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

Review 8.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 9.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

10.  Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms.

Authors:  Benedikt Schoser; Lubov Timchenko
Journal:  Curr Genomics       Date:  2010-04       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.